查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1665183

抗高血压药物市场机会、成长动力、产业趋势分析与 2025 - 2034 年预测

Antihypertensive Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年全球抗高血压药物市场价值为 239 亿美元，预计 2025 年至 2034 年的年复合成长率(CAGR) 为 4.1%。

抗高血压药物市场 - IMG1

随着人口老化以及不良饮食、压力、缺乏运动等生活方式因素的持续存在，高血压发病率持续上升，推动了对有效治疗的需求。药物配方的不断进步，加上远端监控和个人化用药计画等数位健康技术的整合，正在重塑治疗格局。此外，人们对高血压不控制可引发的併发症（如心臟病和中风）的认识不断提高，这鼓励人们进行早期诊断和积极治疗，从而确保了对抗高血压药物的持续需求。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 239亿美元
预测值 355亿美元
复合年增长率 4.1％

根据治疗类型，市场分为利尿剂、血管紧张素转换酶 (ACE) 抑制剂、血管紧张素受体阻断剂、β 受体阻断剂、钙通道阻断剂、肾素抑制剂、α 受体阻断剂、血管扩张剂和其他治疗。 2024 年，利尿剂领域占最大份额，为 22.4%，这得益于噻嗪类利尿剂的广泛使用，该类药物因其降低血压的功效而受到认可。该部门还包括袢利尿剂和保钾利尿剂，以满足不同的治疗需求。另一个主要类别是β受体阻断剂，它进一步细分为β-1选择性和内在拟交感神经药物变异体，可根据患者的个别需求提供个人化的解决方案。

根据药物类型，市场分为原发性高血压治疗药物和继发性高血压治疗药物。 2024 年原发性高血压治疗占据主导地位，占有 90.8% 的市场份额，反映了该疾病在全球范围内的高盛行率。原发性高血压通常与生活方式和遗传因素有关，凸显了对有效的长期治疗方案的需求日益增长。

美国仍然是抗高血压药物市场的主导者，2024 年的收入为 90 亿美元。创新疗法的监管批准使患者能够获得尖端药物，从而进一步推动市场成长。对早期诊断活动和先进治疗方案的关注也正在加速全国的采用率。

目录

第 1 章：方法论与范围

  • 市场范围和定义
  • 研究设计
    • 研究方法
    • 资料收集方法
  • 基础估算与计算
    • 基准年计算
    • 市场估计的主要趋势
  • 预测模型
  • 初步研究和验证
    • 主要来源
    • 资料探勘来源

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业衝击力
    • 成长动力
      • 高血压盛行率不断上升
      • 高血压药物研发及製剂进展
      • 对高血压风险的认知不断提高
      • 数位健康解决方案与治疗策略的整合
    • 产业陷阱与挑战
      • 抗高血压治疗期间服药顺从性差
      • 存在严格的规定
  • 成长潜力分析
  • 监管格局
  • 技术格局
  • 专利分析
  • 差距分析
  • 未来市场趋势
  • 波特的分析
  • PESTEL 分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 策略展望

第 5 章：市场估计与预测：按疗法，2021 – 2034 年

  • 主要趋势
  • 利尿剂
    • 噻嗪类利尿剂
    • 袢利尿剂
    • 保钾利尿剂
  • 血管紧张素转换酶 (ACE) 抑制剂
  • 血管张力素受体阻断剂
  • β受体阻断剂
    • Beta-1选择性
    • 内在拟交感神经药
  • 钙通道阻断剂
  • 肾素抑制剂
  • 阿尔法受体阻断剂
  • 血管扩张剂
  • 其他疗法

第 6 章：市场估计与预测：按药物类型，2021 年至 2034 年

  • 主要趋势
  • 原发性高血压
  • 继发性高血压

第 7 章：市场估计与预测：按管理路线，2021 年至 2034 年

  • 主要趋势
  • 口服
  • 注射剂
  • 其他给药途径

第 8 章：市场估计与预测：按配销通路，2021 年至 2034 年

  • 主要趋势
  • 零售药局
  • 医院药房
  • 网路药局

第 9 章：市场估计与预测：按地区，2021 年至 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第十章：公司简介

  • AbbVie
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Company
  • Johnson & Johnson Services
  • Lupin
  • Merck & Co
  • Noden Pharma DAC
  • Novartis AG
  • Pfizer
  • Sanofi
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
  • Torrent Pharmaceuticals
简介目录
Product Code: 12662

The Global Antihypertensive Drugs Market, valued at USD 23.9 billion in 2024, is set to expand at a compound annual growth rate (CAGR) of 4.1% from 2025 to 2034. This growth is largely driven by the increasing prevalence of hypertension worldwide, a condition often referred to as the "silent killer" due to its asymptomatic nature and severe health risks.

Antihypertensive Drugs Market - IMG1

As populations age and lifestyle factors such as poor diet, stress, and lack of exercise persist, hypertension rates continue to rise, fueling the demand for effective treatments. Continuous advancements in drug formulations, coupled with the integration of digital health technologies like remote monitoring and personalized medication plans, are reshaping treatment landscapes. Furthermore, heightened awareness of the complications associated with unmanaged hypertension, such as heart disease and stroke, is encouraging early diagnosis and proactive treatment adoption, ensuring a sustained demand for antihypertensive drugs.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$23.9 Billion
Forecast Value$35.5 Billion
CAGR4.1%

The market is categorized by therapy type into diuretics, ACE inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, renin inhibitors, alpha-blockers, vasodilators, and other treatments. In 2024, the diuretics segment commanded the largest share at 22.4%, thanks to the widespread use of thiazide diuretics, which are recognized for their effectiveness in reducing blood pressure. This segment also includes loop and potassium-sparing diuretics, catering to diverse treatment requirements. Beta blockers, another key category, are further segmented into beta-1 selective and intrinsic sympathomimetic variants, offering personalized solutions based on individual patient needs.

By drug type, the market divides into treatments for primary and secondary hypertension. Primary hypertension treatments dominated with a commanding 90.8% market share in 2024, reflecting the high global prevalence of this condition. Primary hypertension, often linked to lifestyle and genetic factors, underscores the growing need for effective, long-term treatment options.

The United States remains a dominant player in the antihypertensive drugs market, generating USD 9 billion in revenue in 2024. This leadership is attributed to the high incidence of hypertension, coupled with robust healthcare infrastructure and significant investment in research and development. Regulatory approvals for innovative therapies are enabling patients to access cutting-edge medications, further driving market growth. The focus on early diagnosis campaigns and advanced treatment protocols is also accelerating adoption rates across the country.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing prevalence of hypertension
      • 3.2.1.2 Advances in hypertensive drug development and formulations
      • 3.2.1.3 Growing awareness about the risks of hypertension
      • 3.2.1.4 Integration of digital health solutions in treatment strategies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Poor medication adherence during antihypertensive treatments
      • 3.2.2.2 Presence of stringent regulations
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Patent analysis
  • 3.7 Gap analysis
  • 3.8 Future market trends
  • 3.9 Porter’s analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy outlook

Chapter 5 Market Estimates and Forecast, By Therapy, 2021 – 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Diuretics
    • 5.2.1 Thiazide diuretics
    • 5.2.2 Loop diuretics
    • 5.2.3 Potassium-sparing diuretics
  • 5.3 ACE inhibitors
  • 5.4 Angiotensin receptor blockers
  • 5.5 Beta blockers
    • 5.5.1 Beta-1 selective
    • 5.5.2 Intrinsic sympathomimetic
  • 5.6 Calcium channel blockers
  • 5.7 Renin inhibitors
  • 5.8 Alpha-blockers
  • 5.9 Vasodilators
  • 5.10 Other therapies

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 – 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Primary hypertension
  • 6.3 Secondary hypertension

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Injectables
  • 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Retail pharmacy
  • 8.3 Hospital pharmacy
  • 8.4 Online pharmacy

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 AbbVie
  • 10.2 AstraZeneca
  • 10.3 Bayer AG
  • 10.4 Boehringer Ingelheim International GmbH
  • 10.5 Daiichi Sankyo Company
  • 10.6 Johnson & Johnson Services
  • 10.7 Lupin
  • 10.8 Merck & Co
  • 10.9 Noden Pharma DAC
  • 10.10 Novartis AG
  • 10.11 Pfizer
  • 10.12 Sanofi
  • 10.13 Sun Pharmaceutical Industries
  • 10.14 Takeda Pharmaceutical
  • 10.15 Torrent Pharmaceuticals